Stock Events

Stock Events

SELLAS Life Sciences Group 

€4.17
277
-€0.13-3.14% Today

Statistics

Day High
4.17
Day Low
4.17
52W High
5.25
52W Low
1.22
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 11
€5,470.19
Dec 10
€9,590.47
Sep 10
€3,414.6
Jun 10
€1,934.94
Mar 10
€1,934.94
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7MayExpected
Q4 2025
Next
-0.05
-0.05
-0.05
-0.04
Expected EPS
-0.051203399999999996
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RXK3.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap279.67B
Novartis is a large pharmaceutical company with a broad oncology portfolio, including cancer vaccines and immunotherapies, competing on a larger scale with SELLAS.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. has a strong presence in the cancer immunotherapy market with products like Keytruda, competing with SELLAS's cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb Company offers a range of cancer immunotherapies, making it a competitor to SELLAS in the oncology market.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a diversified portfolio that includes oncology products, competing with SELLAS in the development and marketing of cancer treatments.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. is involved in the discovery and development of innovative human therapeutics, including cancer treatments, competing with SELLAS's focus areas.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca PLC has a strong oncology unit that develops cancer immunotherapies, making it a competitor to SELLAS in the global oncology market.

About

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Show more...
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Employees
15
Country
United States
ISIN
US81642T2096

Listings

MU
DE
RXK3.MU
XNAS
US
SLS
STU
DE
RXK3.STU
BOATS
BOATS
SLS.BOATS

0 Comments

Share your thoughts

FAQ

What is SELLAS Life Sciences Group stock price today?▼
The current price of RXK3.MU is €4.17 EUR — it has decreased by -3.14% in the past 24 hours. Watch SELLAS Life Sciences Group stock price performance more closely on the chart.
What is SELLAS Life Sciences Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange SELLAS Life Sciences Group stocks are traded under the ticker RXK3.MU.
Is SELLAS Life Sciences Group stock price growing?▼
RXK3.MU stock has fallen by -1.07% compared to the previous week, the month change is a +14.58% rise, over the last year SELLAS Life Sciences Group has showed a +180.47% increase.
When is the next SELLAS Life Sciences Group earnings date?▼
SELLAS Life Sciences Group is going to release the next earnings report on May 07, 2026.
What were SELLAS Life Sciences Group earnings last quarter?▼
RXK3.MU earnings for the last quarter are -0.04 EUR per share, whereas the estimation was -0.05 EUR resulting in a +21.05% surprise. The estimated earnings for the next quarter are N/A EUR per share.
Does SELLAS Life Sciences Group pay dividends?▼
Yes, RXK3.MU dividends are paid quarterly. The last dividend per share was 5,470.19 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does SELLAS Life Sciences Group have?▼
As of May 06, 2026, the company has 15 employees.
In which sector is SELLAS Life Sciences Group located?▼
SELLAS Life Sciences Group operates in the Health & Wellness sector.
When did SELLAS Life Sciences Group complete a stock split?▼
SELLAS Life Sciences Group has not had any recent stock splits.
Where is SELLAS Life Sciences Group headquartered?▼
SELLAS Life Sciences Group is headquartered in New York, United States.